Diprotin A TFA Ile-Pro-Ile TFA,99.14%

产品编号:Bellancom-111174A| CAS NO:209248-71-5| 分子式:C19H32F3N3O6| 分子量:455.47

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-111174A
650.00 杭州 北京(现货)
Bellancom-111174A
990.00 杭州 北京(现货)
Bellancom-111174A
2100.00 杭州 北京(现货)
Bellancom-111174A
2900.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

Diprotin A TFA Ile-Pro-Ile TFA

产品介绍 Diprotin A TFA (Ile-Pro-Ile TFA) 是二肽基肽酶 IV (DPP-IV) 的抑制剂。
生物活性

Diprotin A TFA (Ile-Pro-Ile TFA) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).

体外研究

Diprotin A increases the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupts endothelial cell-to-cell junctions, which are attenuated by CXCR4 (receptor of SDF-1α)-blocker or Src-inhibitor.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

In the model of retinopathy of prematurity, Diprotin A increases not only retinal vascularity but also leakage. Additionally, in the murine diabetic retinopathy model, Diprotin A increases the phosphorylation of Src and VE-cadherin and aggravates vascular leakage in the retinas. Collectively, Diprotin A induces vascular leakage by augmenting the SDF-1α/CXCR4/Src/VE-cadherin signaling pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

In the model of retinopathy of prematurity, Diprotin A increases not only retinal vascularity but also leakage. Additionally, in the murine diabetic retinopathy model, Diprotin A increases the phosphorylation of Src and VE-cadherin and aggravates vascular leakage in the retinas. Collectively, Diprotin A induces vascular leakage by augmenting the SDF-1α/CXCR4/Src/VE-cadherin signaling pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状Solid
溶解性数据
In Vitro: 

H2O : ≥ 77.5 mg/mL (170.15 mM)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1955 mL 10.9777 mL 21.9553 mL
5 mM 0.4391 mL 2.1955 mL 4.3911 mL
10 mM 0.2196 mL 1.0978 mL 2.1955 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 100 mg/mL (219.55 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服